Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Esneux – page 66

1 367 clinical trials in Esneux, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Esneux at a glance
1 367
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 367 trials in Esneux

Open in trial search

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Study on the Safety and Tolerability of WVE-006 for Patients with Alpha-1 Antitrypsin Deficiency (AATD) Pi*ZZ

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:WVE-006
  • Sponsor:Wave Life Sciences Ireland Limited

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Rectal cancer

Not recruiting

Study on Induction Chemotherapy with Irinotecan, Folinic Acid, Fluorouracil, and Oxaliplatin for Patients with High-Risk Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Catharina Ziekenhuis Stichting

Mantle cell lymphoma

Not recruiting

Study on Ibrutinib, CD20 Ab and Venetoclax for Patients with Untreated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:LYSARC

Obesity

Not recruiting

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Narcolepsy

Not recruiting

Efficacy and Safety of E2086 in Adults with Narcolepsy: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ledasorexton
  • Sponsor:Eisai Limited

Breast cancer+2

Not recruiting

Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Celcuity Inc.

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Novartis Pharma AG

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Esneux

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) optimization in patients with chronic usage patterns. This study explores effective deprescribing strategies for individuals without clear long-term PPI indications.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Therapy Alternatives

The investigation compares on-demand PPI use and alginate formulation replacement against traditional gradual dose reduction, aiming to establish more effective treatment protocols for gastrointestinal conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.